The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
High total metabolic tumor volume at baseline predicts survival independent of response to therapy
Open accessAbstract
Early identification of ultra-risk diffuse large B-cell lymphoma (DLBCL) patients is needed to aid stratification to innovative treatment. Previous studies suggested high baseline total metabolic tumor volume (TMTV) negatively impacts survival of DLBCL patients. We analyzed the prognostic impact of TMTV and prognostic indices in DLBCL patients, aged 60 to 80 years, from the phase 3 REMARC study that randomized responding patients to R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) into maintenance lenalidomide or placebo. TMTV was computed on baseline positron emission tomography/computed tomography using the 41% maximum standardized uptake value method; the optimal TMTV cutoff for progression-free (PFS) and overall survival (OS) was determined and confirmed by a training validation method. There were 301 out of 650 evaluable patients, including 192 patients classified as germinal center B-cell–like (GCB)/non-GCB and MYC/BCL2 expressor. Median baseline TMTV was 238 cm3; optimal TMTV cutoff was 220 cm3. Patients with high vs low TMTV showed worse/higher Eastern Cooperative Oncology Group performance status (ECOG PS) ≥2, stage III or IV disease, >1 extranodal site, elevated lactate dehydrogenase, International Prognostic Index (IPI) 3-5, and age-adjusted IPI 2-3. High vs low TMTV significantly impacted PFS and OS, independent of maintenance treatment. Although the GCB/non-GCB profile and MYC expression did not correlate with TMTV/survival, BCL2 >70% impacted PFS and could be stratified by TMTV. Multivariate analysis identified baseline TMTV and ECOG PS as independently associated with PFS and OS. Even in responding patients, after R-CHOP, high baseline TMTV was a strong prognosticator of inferior PFS and OS. Moreover, TMTV combined with ECOG PS may identify an ultra-risk DLBCL population. This trial was registered at www.clinicaltrials.gov as #NCT01122472.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0
Boellaard, R., Delgado-Bolton, R., Oyen, W. J. G., Giammarile, F., Tatsch, K., Eschner, W., Verzijlbergen, F. J., Barrington, S. F., Pike, L. C., Weber, W. A., et al. (2015) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-014-2961-x · Cited by 3,303
Cited by
Susanibar‐Adaniya, S., & Barta, S. K. (2021) · American Journal of Hematology · doi:10.1002/ajh.26151 · Cited by 388
Metadata
- Authors
- Vercellino, L., Cottereau, A.-S., Casasnovas, O., Tilly, H., Feugier, P., Chartier, L., Fruchart, C., Roulin, L., Oberic, L., Pica, G. M., Ribrag, V., Abraham, J., Simon, M., Gonzalez, H., Bouabdallah, R., Fitoussi, O., Sebban, C., López-Guillermo, A., Sanhes, L., Morschhauser, F., Trotman, J., Corront, B., Choufi, B., Snauwaert, S., Godmer, P., Briere, J., Salles, G., Gaulard, P., Meignan, M., & Thieblemont, C.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2020-04-16
- Volume
- 135
- Issue
- 16
- Pages
- 1396-1405
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W3002263815
- Cited by
- 186
- References
- 1
- FWCI
- 16.94
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: High total metabolic tumor volume at baseline predicts survival independent of response to therapy. https://app.cochat.ai/papers/10.1182/blood.2019003526
- The paper
- Vercellino, L., Cottereau, A.-S., Casasnovas, O., Tilly, H., Feugier, P., Chartier, L., Fruchart, C., Roulin, L., Oberic, L., Pica, G. M., Ribrag, V., Abraham, J., Simon, M., Gonzalez, H., Bouabdallah, R., Fitoussi, O., Sebban, C., López-Guillermo, A., Sanhes, L., . . . Thieblemont, C. (2020). High total metabolic tumor volume at baseline predicts survival independent of response to therapy. Blood. https://doi.org/10.1182/blood.2019003526
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.